Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
eNq1mF1v2jAUhu/5FVHuSRo+CpsC1cbaDanVGAVt2k1lkkMxc+3UHwT26+cQusLkqMPgy8TOe058Xj8+cny1fiLeCrjAjPb8KLjwPaAJSzF97PnTyU2961/1a/ESrdDrtIaeF0SR7yUECdHzi9FgBoiK4Mfd7SfQ3wP3+zUvZrMlJPJgnpKYBF+QWNyhrJjjxSuGU+8J5IKlPT9TcvvWi4XkOot+zvgvkaEE4nD3Zn90+dDafx+Hhdh/qCoB/BbRR6MoUCvNRHEOVA6QhEfGNxX5Nq20sRiDYIonMEJyMeJshVNIjSHmiAiwCjLP03vgKwKyCGIUD5fJk7ASR0u0HsPz0Jz0Bz06kGtZv6hHnW7rstlqdduNZsMqFN9bKnMV9E+EyUPUaUdRpxMCDWFDAFlWZsS4RMRRTbAYHNrKURwOz2/WPsUiI2gTLEVmu1SIIz0MXG9+dz9S/MGEaxwRvWb/6FNFSHhk1tMdLBxlXLBowBSVFcy4GdsuxIBRCevqitphTq53XsQgzif7m1Ez4kdqRnBiCzSNHAVCTsfDap6dDwUfkYApd8eC75imLBfnZ8x+TR1ln20xaRTNeBo9NN51L6N223oL/dQGqjhdrhVnGYSaPlicApUhnbNTcaI9aZZ6ceSZzLjtcFiCCFT0OHVLrmgXvrRkznzubg+VA0bRz9cTW3N8U8A399tHozROe3/LagddFyTXVqxM/Hhjl/vbSferuJkbCykz8T4M8zwPFkjUBdKrFMz5mam+d4y667ydnNVl71KS0VHqs/LIO64+tvvsrdP81A519/2uEzbGkFzBCbUokewMnMPr87P4tT11lvbogB3uwmxbSSQxo66aHDUzKp5Gf11XesM1IL7O57jiJqTSl3FY3sL0a3FY3MD0a38A1VrhNw==
dmNzKv8rcC7Y0Xvw
